基于罗马IV标准且有限检查的肠易激综合征诊断在二级医疗中具有持久性
该研究纳入373例符合罗马IV标准、转诊至英国单一诊所的成人肠易激综合征(IBS)患者,平均随访4.2年,评估再转诊、再检查和漏诊器质性疾病率。结果62例(16.6%)再转诊,仅4例(1.1%)发现新的相关器质性疾病;结论认为有限检查后的罗马IV标准IBS诊断安全且持久。
要点
- 平均随访4.2年(总随访1565年),再转诊率16.6%(62/373)。
- 再检查率:IBS再转诊组60.0%(21/35) vs 其他症状再转诊组81.5%(22/27),P = .12。
- 漏诊相关器质性疾病仅4例(占再检查者9.3%,占全队列1.1%)。
核心结论
- 尽管总体每6例患者中约有1例因胃肠道症状再转诊,近10%因持续IBS症状再转诊且再检查率较高,漏诊器质性疾病仅约1%,基于有限检查的罗马IV标准IBS诊断安全且持久。
研究设计与样本
- 收集2016年9月至2020年3月期间转诊至英国单一诊所、符合罗马IV标准IBS的373例特征明确的成人的完整症状数据。
- 所有患者在诊断前接受相对标准化的检查以排除相关器质性疾病;随访至2022年12月,评估再转诊率、再检查率和漏诊器质性疾病率。
主要发现
- 平均每例随访4.2年(所有患者总随访1565年),62例(16.6%)再转诊;其中35例(56.5%)因IBS再转诊,27例(43.5%)因其他胃肠道症状再转诊。
- 35例因IBS再转诊者中,仅5例(14.3%)由症状变化引起。
- 再检查:35例因IBS再转诊者中21例(60.0%)接受再检查,27例因其他症状再转诊者中22例(81.5%)接受再检查(P = .12)。
- 仅发现4例(占再检查者的9.3%,占整个队列的1.1%)新的相关器质性疾病,可能解释基线IBS症状:因IBS再转诊者中1例慢性钙化性胰腺炎;因其他胃肠道症状再转诊者中1例未分类炎症性肠病、1例中度胆汁酸性腹泻、1例小肠梗阻。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is a positive diagnosis, made using symptom-based criteria and limited, judicious, investigation. However, this may lead to uncertainty on the part of clinicians regarding potential for a missed diagnosis of organic gastrointestinal disease. Few studies have examined durability of a diagnosis of IBS, and none have used the current gold standard to diagnose IBS, the Rome IV criteria. METHODS: We collected complete symptom data from 373 well-characterized adults meeting Rome IV criteria for IBS referred to a single UK clinic between September 2016 and March 2020. All patients underwent relatively standardized work-up to exclude relevant organic disease before diagnosis. We followed these individuals up to December 2022, assessing rates of rereferral, reinvestigation, and missed organic gastrointestinal disease. RESULTS: During a mean follow-up of 4.2 years per patient (total follow-up in all patients, 1565 years), 62 (16.6%) patients were rereferred. Of these, 35 (56.5%) were rereferred for IBS and 27 (43.5%) for other gastrointestinal symptoms. Among the 35 rereferred with IBS this was caused by a change in symptoms in only 5 (14.3%). Reinvestigation was undertaken in 21 (60.0%) of 35 rereferred with IBS and 22 (81.5%) of 27 rereferred with other symptoms (P = .12). Only 4 (9.3% of those reinvestigated and 1.1% of the entire cohort) new cases of relevant organic disease, which may have been responsible for IBS symptoms at baseline, were identified (1 case of chronic calcific pancreatitis among those rereferred with IBS and 1 case each of inflammatory bowel disease-unclassified, moderate bile acid diarrhea, and small bowel obstruction among those rereferred with other gastrointestinal symptoms). CONCLUSIONS: Despite rereferral for gastrointestinal symptoms among 1 in 6 patients overall, with almost 10% rereferred with ongoing IBS symptoms, and substantial reinvestigation rates, missed organic gastrointestinal disease occurred in only 1%. A diagnosis of Rome IV IBS after limited investigation is safe and durable.
引用
- Khasawneh M, Craig OF, Gracie DJ, et al. A Diagnosis of Irritable Bowel Syndrome Using Rome IV Criteria and Limited Investigations is Durable in Secondary Care. Clin Gastroenterol Hepatol. 2023. PMID: 37302448. doi:10.1016/j.cgh.2023.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。